Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application U.S. 13/032,029 entitled, “Compositions for Targeted Delivery of siRNA.” The patent broadly covers compositions, methods, and uses for a new formulation of Arrowhead’s Dynamic Polyconjugate (DPC) siRNA delivery platform, where attachment of siRNA and delivery vehicle is not required to produce high-level, efficient knockdown of target genes. The new IP expands the DPC platform and is used in Arrowhead’s ARC-520 candidate in development for chronic hepatitis B virus (HBV) infection.
“This patent is critical to the commercialization of ARC-520,” said Dr. Chris Anzalone, President and CEO of Arrowhead. “The underlying technology enables us to create candidates with highly potent silencing activity and attractive manufacturing qualities. We continue to work towards a planned phase 1 trial of ARC-520, and are pleased to announce that we had a very productive pre-IND meeting with the FDA, which allows us to maintain our timeline to file an IND in Q2 2013.”
The allowed claims protect an RNAi delivery system consisting of a liver-targeted, endosomolytic polymer synthesized using Arrowhead’s proprietary masking technology co-administered with an RNAi polynucleotide (siRNA) conjugated to a lipophilic or carbohydrate targeting moiety. With this DPC formulation, neither covalent attachment of the siRNA to the endosomolytic polymer nor siRNA/polymer complex formation is required.
Pre-clinical studies have shown co-injection of liver-targeted polymer together with siRNA conjugated to a lipophilic moiety, such as cholesterol, results in a >500-fold increase in the potency when compared to the siRNA-cholesterol alone. This formulation retains the potent endosomal escape capabilities of Arrowhead's DPC platform while facilitating drug production and opening up new targeting opportunities. Additional details and data from pre-clinical studies will be available in upcoming publications in scientific journals.About Arrowhead Research Corporation Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts